FDA grants accelerated approval to zongertinib for non-squamous NSCLC

On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinas

Read the full article here

Related Articles